NASDAQ · MTSR
Healthcare · Biotechnology
$70.50
Down-$0.25 (-0.35%)
Updated Sep 2, 2026, 10:49 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
MTSR does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning MTSR.
MTSR research
Company profile and research snapshot.
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2025 | Leerink Partners | Market Perform | — |
| Sep 9, 2025 | Leerink Partners | Outperform | — |
| Sep 3, 2025 | Cantor Fitzgerald | Overweight | — |
| Aug 28, 2025 | B of A Securities | Buy | — |
| Jun 20, 2025 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
defenseworld.net · Dec 8, 2025
Metsera Inc. (NASDAQ: MTSR - Get Free Report) has been given a consensus rating of "Hold" by the eight analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating on the company.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MTSR.
No results
No recent SID articles mention MTSR.
